Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 929,600 shares, an increase of 562.1% from the February 28th total of 140,400 shares. Currently, 8.1% of the company’s shares are sold short. Based on an average trading volume of 14,530,000 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Several equities research analysts have issued reports on PSTV shares. D. Boral Capital assumed coverage on Plus Therapeutics in a report on Monday, March 17th. They issued a “buy” rating and a $9.00 price target for the company. Ascendiant Capital Markets decreased their price objective on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Plus Therapeutics in a research report on Tuesday, November 26th.

Plus Therapeutics Stock Performance

Shares of PSTV stock traded up $0.04 during trading on Wednesday, hitting $1.47. The company had a trading volume of 6,078,201 shares, compared to its average volume of 3,853,771. The firm has a market capitalization of $8.67 million, a P/E ratio of -0.58 and a beta of 0.73. The stock’s 50-day moving average price is $1.10 and its 200 day moving average price is $1.23. Plus Therapeutics has a one year low of $0.24 and a one year high of $2.67.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.